Samuel Whiting
CIK 1870373 · View on SEC EDGAR ↗
First SEC filing: June 30, 2021 · Latest: June 30, 2021
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 6, 2022 | TPST | P | 1,700 | $4.80 | $8,160 | 1,901 Direct | +845.77% | Acquired | -98.3% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 3, 2024 | TPST | Employee Stock Option (right to buy) | Common Stock (100,000) | $4.66 | Jan. 2, 2034 | 100,000 | Acquired |
| Oct. 11, 2023 | TPST | Employee Stock Option (right to buy) | Common Stock (325,000) | $9.77 | Oct. 10, 2033 | 325,000 | Acquired |
| Jan. 3, 2023 | TPST | Employee Stock Option (right to buy) | Common Stock (69,700) | $1.23 | Jan. 2, 2033 | 69,700 | Acquired |
| June 21, 2022 | TPST | Stock Option (Right to Buy) | Common Stock (55,680) | $2.35 | June 20, 2032 | 55,680 | Acquired |
| Jan. 4, 2022 | TPST | Stock Option (Right to Buy) | Common Stock (29,000) | $5.45 | Jan. 3, 2032 | 29,000 | Acquired |
| June 25, 2021 | TPST | Stock Option (Right to Buy) | Common Stock (61,945) | $5.90 | Nov. 15, 2030 | 61,945 | Acquired |
| June 25, 2021 | TPST | Stock Option (Right to Buy) | Common Stock (3,018) | $10.25 | March 9, 2031 | 3,018 | Acquired |
| June 25, 2021 | TPST | Stock Option (Right to Buy) | Common Stock (540,231) | $26.40 | April 28, 2031 | 540,231 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
TPST
Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $481,749 | — | — | $391,200 | $175,838 | — | $13,800 | $1,062,587 |
| 2023 | $454,480 | — | — | — | $199,971 | — | $13,200 | $3,384,949 |
| 2022 | $437,000 | — | — | — | $142,025 | — | $12,200 | $833,398 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.